Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. NNNN
NNNN logo

NNNN Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
24.240
Open
22.990
VWAP
21.92
Vol
44.47K
Mkt Cap
3.01B
Low
20.580
Amount
974.57K
EV/EBITDA(TTM)
--
Total Shares
143.89M
EV
905.21M
EV/OCF(TTM)
--
P/S(TTM)
--
Anbio Biotechnology is a Germany-based medical device company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).
Show More

Events Timeline

(ET)
2026-02-03
12:10:00
Anbio Biotechnology Rises 20% to $29.60
select
2026-02-02 (ET)
2026-02-02
13:30:00
Anbio Biotechnology Trading Halted Due to Volatility
select
2026-01-29 (ET)
2026-01-29
15:00:00
Anbio Biotechnology Trading Halted Due to Volatility
select
2025-12-30 (ET)
2025-12-30
12:10:00
Anbio Biotechnology Shares Down 5.8% to $30.50
select
2025-12-23 (ET)
2025-12-23
12:10:00
Anbio Biotechnology Shares Down 7.0% to $31.15
select
2025-12-17 (ET)
2025-12-17
12:10:00
Anbio Biotechnology Stock Rises 11.2% to $31.14
select
2025-11-18 (ET)
2025-11-18
12:00:24
Anbio Biotechnology Sees 15.4% Increase
select
2025-11-03 (ET)
2025-11-03
12:02:28
Anbio Biotechnology Experiences a 19.5% Decline
select

News

Barron's
4.5
01-16Barron's
S&P 500 Futures Rise in Pre-Market Trading; QXO and Mosaic Underperform
  • Market Opening: U.S. stock markets are set to open in two hours.

  • AST SpaceMobile Inc. Performance: AST SpaceMobile Inc. (ASTS) saw a 6.8% increase in pre-market trading.

  • Sandisk Corp. Performance: Sandisk Corp. (SNDK) experienced a 5.3% rise in pre-market trading.

  • Overall Market Sentiment: The pre-market gains indicate positive sentiment among investors for these companies.

Benzinga
2.0
2025-12-04Benzinga
UiPath Shares Rise Approximately 9%; Check Out 20 Stocks Making Moves in Premarket Trading
  • UiPath Financial Results: UiPath Inc. shares rose 8.7% in pre-market trading after reporting third-quarter adjusted earnings of 16 cents per share and revenue of $411.11 million, both exceeding estimates.

  • Other Gainers: Several stocks saw significant pre-market gains, including Polyrizon Ltd (+158.1%), Nauticus Robotics, Inc (+34%), and Picard Medical, Inc (+22.3%), driven by positive news and developments.

  • Notable Losers: Virax Biolabs Group Ltd fell 16.2% after announcing a private placement, while Treasure Global Inc declined 13.3% following a reverse stock split and Nasdaq delisting notification.

  • Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies like Axogen, Inc and Hyster-Yale, Inc also experiencing notable increases.

Newsfilter
5.0
2025-08-09Newsfilter
Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
  • Launch of Chikungunya Rapid Test: Anbio Biotechnology has introduced a Chikungunya IgM/IgG Rapid Test to aid in the quick diagnosis of Chikungunya fever, crucial for differentiating it from other arboviral infections as cases rise in tropical regions.

  • Advancements in PCR Technology: The company also unveiled the AP-100 Ultra-Fast PCR system, which provides lab-grade testing capabilities in just 15 minutes without the need for nucleic acid extraction, enhancing diagnostic speed and accuracy in both centralized and decentralized healthcare settings.

Yahoo Finance
5.0
2025-08-09Yahoo Finance
Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
  • Anbio's New Diagnostic Tools: Anbio Biotechnology has launched a Chikungunya IgM/IgG Rapid Test to aid in the timely detection of Chikungunya fever, alongside the AP-100 Ultra-Fast PCR system for rapid molecular diagnostics, enhancing outbreak response capabilities.

  • Focus on Speed and Flexibility: The AP-100 provides lab-grade testing results within 15 minutes without the need for nucleic acid extraction, and is designed to expand its testing portfolio to include various infectious diseases, supporting global health preparedness.

Benzinga
2.0
2025-07-08Benzinga
Microchip Technology, Tesla, Humacyte And Other Big Stocks Moving Higher On Tuesday
  • Stock Market Overview: U.S. stocks showed mixed results with the Dow Jones dropping over 100 points, while Microchip Technology shares surged 4.1% after an analyst raised its price target from $78 to $85.

  • Notable Stock Performances: Several companies experienced significant gains, including Humacyte (up 27.4%), Wolfspeed (up 18.2%), and SharpLink Gaming (up 16.4%), amidst various announcements and market expectations.

Benzinga
9.5
2025-06-26Benzinga
H.B. Fuller Posts Better-Than-Expected Earnings, Joins AeroVironment, MillerKnoll And Other Big Stocks Moving Higher On Thursday
  • U.S. Stock Market Performance: U.S. stocks rose, with the Nasdaq Composite gaining approximately 100 points; notable gains were seen in H.B. Fuller Company, which surged 10.8% after reporting better-than-expected earnings and raising its FY2025 EPS guidance.

  • Significant Stock Gains: Other companies like BlackSky Technology, Worthington Steel, and Rocket Lab also experienced substantial stock increases, with BlackSky's shares jumping 16.5% following a price target upgrade from Canaccord Genuity.

Valuation Metrics

The current forward P/E ratio for Anbio Biotechnology (NNNN.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Anbio Biotechnology's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what is the best day trade of today?
Intellectia · 53 candidates
Price: $5.00 - $100.00Price Change Pct: $4.00 - $20.00Relative Vol: >= 2One Day Predict Return: >= 0.0%Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
AVTX logo
AVTX
Avalo Therapeutics Inc
257.14M
TSQ logo
TSQ
Townsquare Media Inc
118.19M
CE logo
CE
Celanese Corp
6.39B
MESO logo
MESO
Mesoblast Ltd
2.32B
SMX logo
SMX
SMX (Security Matters) PLC
171.43M
DFH logo
DFH
Dream Finders Homes Inc
1.95B
what stocks will
Intellectia · 3459 candidates
Market Cap: >= 100.00MPrice: $1.00 - $200.00Monthly Average Dollar Volume: >= 100,000
Ticker
Name
Market Cap$
top bottom
KELYB logo
KELYB
Kelly Services Inc
510.65M
PSNY logo
PSNY
Polestar Automotive Holding UK PLC
1.21B
PAHC logo
PAHC
Phibro Animal Health Corp
1.66B
FORM logo
FORM
FormFactor Inc
5.43B
LBRX logo
LBRX
LB Pharmaceuticals Inc
526.22M
ENSG logo
ENSG
Ensign Group Inc
10.05B
update list for stock prices between 5-50
Intellectia · 64 candidates
Price: $5.00 - $50.00Moving Average Relationship: PriceBelowMA20Week Price Change Pct: <= $-7.00Month Price Change Pct: <= $-10.00Monthly Average Dollar Volume: >= 800,000
Ticker
Name
Market Cap$
top bottom
VENU logo
VENU
Venu Holding Corp
364.84M
RGNX logo
RGNX
Regenxbio Inc
698.09M
NNNN logo
NNNN
Anbio Biotechnology
2.89B
SMX logo
SMX
SMX (Security Matters) PLC
156.97M
NRIM logo
NRIM
Northrim BanCorp Inc
510.78M
AD logo
AD
Array Digital Infrastructure Inc
4.03B
stocks bearish for a week
Intellectia · 82 candidates
Price: >= $5.00Moving Average Relationship: PriceBelowMA20Week Price Change Pct: <= $-7.00Month Price Change Pct: <= $-10.00Monthly Average Dollar Volume: >= 800,000
Ticker
Name
Market Cap$
top bottom
VENU logo
VENU
Venu Holding Corp
364.84M
RGNX logo
RGNX
Regenxbio Inc
698.09M
NNNN logo
NNNN
Anbio Biotechnology
2.89B
HUM logo
HUM
Humana Inc
25.28B
CVLT logo
CVLT
Commvault Systems Inc
4.05B
SMX logo
SMX
SMX (Security Matters) PLC
156.97M

Whales Holding NNNN

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Anbio Biotechnology (NNNN) stock price today?

The current price of NNNN is 20.93 USD — it has decreased -5.76

What is Anbio Biotechnology (NNNN)'s business?

Anbio Biotechnology is a Germany-based medical device company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).

What is the price predicton of NNNN Stock?

Wall Street analysts forecast NNNN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NNNN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Anbio Biotechnology (NNNN)'s revenue for the last quarter?

Anbio Biotechnology revenue for the last quarter amounts to 92.32 USD, increased 38.10

What is Anbio Biotechnology (NNNN)'s earnings per share (EPS) for the last quarter?

Anbio Biotechnology. EPS for the last quarter amounts to USD, decreased

How many employees does Anbio Biotechnology (NNNN). have?

Anbio Biotechnology (NNNN) has 27 emplpoyees as of March 11 2026.

What is Anbio Biotechnology (NNNN) market cap?

Today NNNN has the market capitalization of 3.01B USD.